DB14798InvestigationalProtein Based Therapies
Afasevikumab is under investigation in clinical trial NCT01480310 (Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of Subcutaneous MCAF5352A in Healthy Volunteers).
- Mechanism
- Curator reviewed
Pharmacologically active on Interleukin-17A
- Also known as
- MCAF5352A
Resolves to
Compound
Targets
What you can answer from here — as of June 15, 2026
Which drugs share a target with Afasevikumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account